Circulation Heart Failure · 2021 · 38 citations · 29 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical CardiologyInterventional CardiologyCardiac BiomarkersCardiac MedicationsCardiovascular DiseaseHeart FailureHeart Failure PharmacotherapyAngiotensin Receptor-neprilysin InhibitorsB-type Natriuretic PeptidesCardiac RemodelingCardiovascular BiomarkersCardiovascular Disease BiomarkersEchocardiographic BiomarkersMyocardial Injury AssessmentMyocardial Injury Markers
Background: Sacubitril/valsartan (S/V) treatment is associated with reverse cardiac remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial injury, such as NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-cTnT (high-sensitivity cardiac troponin T), and soluble suppressor of tumorigenicity 2 (sST2). How longitudinal changes in these biomarkers analyzed collectively are associated with cardiac remodeling in patients with heart failure with reduced ejection fraction treated with S/V is uncertain. Methods: In a prospective study of S/V in patients with heart failure with reduced ejection fraction, this prespecified exploratory analysis included patients with serially collected biomarkers and echocardiographic measures of cardiac remodeling through 12 months of treatment. A multivariate latent growth curve model assessed associations between simultaneous changes in biomarkers and left ventricular ejection fraction and left atrial volume index. Results: Seven hundred fifteen out of 794 total study participants were included (mean age 65 years, 73% male). Mean baseline left ventricular ejection fraction and left atrial volume index were 29% and 40 mL/m 2 , respectively. Adjusted geometric mean baseline concentrations for biomarkers included NT-proBNP of 649 pg/mL, hs-cTnT of 15.9 ng/L, and sST2 of 24.7 ng/mL. Following initiation of S/V, circulating concentrations of NT-proBNP, hs-cTnT, and sST2 significantly decreased within 30 days and remained significantly different than baseline at all subsequent timepoints. From baseline to month 12, decreases in adjusted biomarker concentrations averaged −27.9% (95% CI, −35.1% to −20.7%; P <0.001) for NT-proBNP; −6.7% (95% CI, −8.8% to −4.7%; P <0.001) for hs-cTnT; and −1.6% (95% CI, −2.9% to −0.4%; P <0.001) for sST2. NT-proBNP concentrations were predictive of later changes in hs-cTnT. The magnitude of reductions in NT-proBNP and hs-cTnT concentrations associated with improvements in left ventricular ejection fraction and left atrial volume index. There was no association between changes in sST2 and changes in other measures. Conclusions: Following initiation of S/V, NT-proBNP, hs-cTnT, and sST2 concentrations decreased significantly. Longitudinal changes in NT-proBNP and hs-cTnT together associated with left atrial and left ventricular reverse remodeling. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02887183.
29
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
John J.V. McMurray, Milton Packer, Akshay S. Desai et al. · New England Journal of Medicine · 2014 · 6.8K citations · Full text
Medicine, Cardiology, Pharmacology +11
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez, David A. Morrow, Adam D. DeVore et al. · New England Journal of Medicine · 2018 · 1.2K citations · Full text
Analytical Validation of a High-Sensitivity Cardiac Troponin T Assay
Evangelos Giannitsis, Kerstin Kurz, Klaus Hallermayer et al. · Clinical Chemistry · 2009 · 1.1K citations · Full text
James L. Januzzi, Margaret F. Prescott, Javed Butler et al. · JAMA · 2019 · 624 citations · Full text
Medicine, Cardiology, Pharmacology +10